Orchid Announces Commercial SNP Scoring Agreement With Lilly
PRINCETON, N.J., Oct. 11 /PRNewswire/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH) today announced that it has established a commercial single nucleotide polymorphism (SNP) genotyping service agreement with Eli Lilly and Company (NYSE: LLY) in which Orchid will perform high throughput SNP scoring on samples provided by Lilly. Further details of the agreement were not disclosed.
"Lilly has a longstanding record of accessing innovative technology," said Russell Granzow, vice president of marketing and business development of Orchid. "Orchid's high throughput MegaSNPatron(TM) SNP scoring facility allows customers to rapidly obtain genotyping results on their study samples. We are very pleased to add Lilly, a world class pharmaceutical company, to our growing list of major pharmaceutical and biotechnology customers and strategic partners."
Orchid's MegaSNPatron facility provides researchers access to accurate, cost-effective genotyping based on Orchid's proprietary SNP-IT(TM) primer extension and related technologies. The MegaSNPatron facility currently has the capability to produce more than 100,000 genotypes per day, and throughput capacity is expected to be expanded to 1,000,000 genotypes per day in 2001.
Orchid BioSciences, Inc. is a provider of products, services and technologies for SNP scoring and genetic diversity analyses. Orchid has developed SNP-IT, its proprietary SNP analysis technology, and markets SNPstream(TM) instruments and SNPware(TM) consumables that rapidly generate highly accurate, cost effective SNP information. Orchid also provides high throughput SNP scoring services to pharmaceutical, agricultural and academic customers through its MegaSNPatron facility, and DNA testing through its GeneScreen facilities, which conduct paternity, forensics and transplantation testing.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding increases in the MegaSNPatron facility's capacity to perform genotypes and the timing of this scale up. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. These and other risk factors are discussed in the Company's Registration Statement on Form S-1 declared effective by the Securities and Exchange Commission on May 4, 2000. Orchid expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Contact: Russell T. Granzow, Vice President, Marketing and Business Development, or Barbara L. Lindheim, Vice President, Strategic Communications, both of Orchid BioSciences, Inc., 609-750-2200; or media - Ernie Knewitz of Noonan/Russo Communications, Inc., 212-696-4455, ext. 204, for Orchid BioSciences, Inc. SOURCE Orchid BioSciences, Inc.
/CONTACT: Russell T. Granzow, Vice President, Marketing and Business Development, or Barbara L. Lindheim, Vice President, Strategic Communications, both of Orchid BioSciences, Inc., 609-750-2200; or media - Ernie Knewitz of Noonan/Russo Communications, Inc., 212-696-4455, ext. 204, for Orchid BioSciences, Inc./
(ORCH LLY) CO: Orchid BioSciences, Inc.; Eli Lilly and Company ST: New Jersey IN: MTC BIO SU: JVN
(END) DOW JONES NEWS 10-11-00
07:25 AM |
